Genzyme is working closely with PTC to completely understand the results of the ongoing additional analyses.
Once PTC and Genzyme have clearer insight on the best path forward globally, they will proactively come back to the community with an update. PTC and Genzyme are aware of the great need for a treatment for nmDBMD, and will continue to partner to investigate various options that may help bring a safe and effective therapy to the community.
For questions outside the USA and Canada please contact Genzyme’s medical information department at email@example.com
For more information relating to the US and Canada please contact PTC’s patient advocacy team at firstname.lastname@example.org"